Wall Street: GLP-1 competitors’ pain is Eli Lilly’s gain

Eli Lil­ly’s stock con­tin­ued its wild ride Wednes­day af­ter lack­lus­ter da­ta from Am­gen’s po­ten­tial GLP-1 com­peti­tor fur­ther demon­strat­ed tirzepatide’s ad­van­tage.

On Wednes­day, Lil­ly shares $LLY spiked near­ly 5% be­fore clos­ing at $725.38, still a 3% in­crease for the day. Those gains were like­ly fu­eled by a less-than-pos­i­tive in­vestor re­sponse to Am­gen’s GLP-1 pro­gram, re­in­forc­ing tirzepatide’s lead­ing po­si­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.